

Product datasheet for TL314686V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

GRAF (ARHGAP26) Human shRNA Lentiviral Particle (Locus ID 23092)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: GRAF (ARHGAP26) Human shRNA Lentiviral Particle (Locus ID 23092)

Locus ID: 23092

Synonyms: GRAF; GRAF1; OPHN1L; OPHN1L1

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: ARHGAP26 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001135608, NM 015071, NM 001349547, NR 146198, NM 015071.1, NM 015071.2,

NM 015071.3, NM 015071.4, NM 015071.5, NM 001135608.1, NM 001135608.2, BC068555,

BC021059, NM 001135608.3

UniProt ID: Q9UNA1

Summary: Interaction of a cell with the extracellular matrix triggers integrin cell surface receptors to

begin signaling cascades that regulate the organization of the actin-cytoskeleton. One of the proteins involved in these cascades is focal adhesion kinase. The protein encoded by this gene is a GTPase activating protein that binds to focal adhesion kinase and mediates the activity of the GTP binding proteins RhoA and Cdc42. Defects in this gene are a cause of juvenile myelomonocytic leukemia (JMML). Multiple transcript variants encoding different

isoforms have been found for this gene. [provided by RefSeq, Mar 2017]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).